Tag:
AstraZeneca
Latest Headlines
Latest Headlines
Another drug study flops at AstraZeneca as CEO braces for bumpy turnaround
In an interview with Reuters yesterday, CEO Pascal Soriot warned that turning around AstraZeneca is going to require a lengthy rebuilding effort.
AstraZeneca homes in on new HQ and research site in Cambridge
Over the next three years the pharma company plans to build a $500 million complex on an 11-acre site at the Cambridge BioMedical Campus.
AstraZeneca picks Cambridge site as ground zero for R&D reinvention
Over the next three years the pharma company plans to build a $500 million complex on its new campus that will house its U.K. operations for biologics and small molecule research as well as the corporate staff now operating in London.
FDA clears Sanofi to compete for 4-in-1 flu vaccine market
The 2013-14 flu season is set to be the most closely watched in years. In February, FDA cleared the use of quadrivalent vaccines which protect against two A and two B strains. GlaxoSmithKline and AstraZeneca began gearing up, and Sanofi will now join them too.
Pearl's porous particle platform nets $1.15B AstraZeneca buyout
In its $1.15 billion buyout of Pearl Therapeutics this week, AstraZeneca bolstered its late-stage drug development with a Phase III inhaled delivery platform to treat respiratory diseases.
Top AstraZeneca exec bows out to helm a biotech
AstraZeneca's announcement early this year that Peter Greenleaf would be "promoted" from the head of MedImmune to the top job in the company's big Latin American division raised a few eyebrows around the industry.
New deal part of Soriot's revised strategy to energize AstraZeneca
AstraZeneca's first-quarter earnings report was a stark indication of why its new CEO Pascal Soriot is scrambling to buy some new drugs the company can lean on.
AstraZeneca bolsters software systems for virtual R&D of neuroscience drugs
AstraZeneca ($AZN) has beefed up its lineup of software vendors for its virtual neuroscience group. A provider of clinical trials software, ePharmaSolutions plans to support AZ's neuroscience group with study apps and cloud computing.
AstraZeneca taps ePharmaSolutions for all-outsourced neuro unit
AstraZeneca is piecing together a team of contractors for its almost virtual neuroscience unit, and the company has signed up with ePharmaSolutions to create a network that will unite its many outsourcers.
UPDATED: AstraZeneca bags another PhIII therapy in $1.15B Pearl buyout
The Pearl Therapeutics buyout gives AstraZeneca's late-stage development director Briggs Morrison a Phase III respiratory therapy just days after the pharma giant was forced to throw in the towel on the rheumatoid arthritis drug fostamatinib.
